Observational studyCalcified tissue international2025
Comparison of Type 2 Diabetes Risk in Osteoporosis Patients Treated with Denosumab or Alendronate: A Nationwide Cohort Study.
Observational study in Calcified tissue international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have suggested potential metabolic effects of anti-osteoporotic medications, but their impact on type 2 diabetes mellitus (T2D) risk remains unclear. This study investigated the incidence of T2D in patients with osteoporosis treated with denosumab or alendronate. Using the Korean Health Insurance Review and Assessment Service database, we identified 316,026 patients who received either denosumab or alendronate between October 2017 and June 2022. After 1:3 propensity score matching, 1136 denosumab users and 3303 alendronate users were included. The primary outcome was incident T2D, defined as a new diagnosis followed by an antidiabetic medication prescription within six months. Over a median follow-up of 4.7 years, 57 (5.0%) denosumab users and 196 (5.9%) alendronate users developed T2D, with incidence rates of 10.7 and 12.4 per 1000 person-years, respectively. Denosumab use was not significantly associated with reduced T2D risk (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.64-1.15). Additional adjustment for chronic kidney disease and fractures during follow-up yielded an HR of 0.84 (95% CI 0.62-1.13; P = 0.25). Fine-Gray competing risk analysis considering death produced similar results (HR 0.84, 95% CI 0.62-1.13; P = 0.24). Subgroup analyses showed consistent findings across sex, age groups, comorbidities, and concurrent medication use. These findings suggest no significant difference in T2D risk between denosumab and alendronate users in osteoporosis patients. Both medications appear to have comparable metabolic effects. Further large-scale studies with longer follow-up are warranted to clarify the long-term impact of osteoporosis treatments on diabetes risk.
Indexed as
Identifiers
40445395What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.